Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Emcure Pharmaceuticals Ltd (EMCURE) is currently trading at 1,443.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics. Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market. The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans. With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products. Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹890.00 and a high of ₹1,585.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Emcure Pharmaceuticals Ltd has a market capitalization of approximately 27,525.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.62 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 27,525.56 Cr, Emcure Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Emcure Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 31.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore, five-year plan to make India a global hub for biopharmaceutical manufacturing, directly benefiting R&D and production of biologics and biosimilars.
The NAI status means the US FDA found no objectionable conditions during its inspection of Emcure's Gujarat facility, confirming its compliance with manufacturing standards and clearing it for regulatory purposes without any required corrective actions.
Bearish
4
Neutral
8
Bullish
2
Bearish
27
Neutral
8
Bullish
11
Bearish
23
Neutral
0
Bullish
9
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2068.60 | 33,247 Cr | 44.75 | 8.74 | 0.73 | 18.88 | 25.16 | 16.00 | |
1451.20 | 27,526 Cr | 31.62 | 5.80 | 0.21 | 16.72 | 19.37 | 9.53 | |
1306.10 | 21,223 Cr | 989.25 | 4.65 | 0.00 | 1.54 | 4.05 | -0.12 | |
997.00 | 17,924 Cr | 11.47 | 2.07 | 0.60 | 17.79 | 21.15 | 14.81 | |
575.95 | 13,924 Cr | 26.17 | 3.50 | 0.26 | 12.88 | 13.37 | 7.86 | |
1221.00 | 12,579 Cr | 41.06 | 6.88 | 0.73 | 17.73 | 23.48 | 15.38 | |
292.15 | 11,163 Cr | 55.99 | 2.95 | 0.00 | 10.47 | 11.28 | 4.65 |
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics.
Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market.
The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans.
With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products.
Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
27,526 Cr
Low Risk
31.6
28.3
1.8
5.8
1,585.50
890.00
Sales CAGR
Profit CAGR
ROE
ROCE
